Literature DB >> 33803151

The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer.

Rina Masadah1, Syahrul Rauf2, Muhammad Yogi Pratama1,3, Claudio Tiribelli3, Devis Pascut3.   

Abstract

Cervical cancer is the fourth leading cause of cancer-related death among women worldwide. The chemotherapeutical agent cisplatin, a small platinum-based compound, is considered as the standard therapy for locally advanced cervical cancer or recurrent cancers, sometimes in combination with radiotherapy or other drugs. However, drug resistance and radio-resistance phenomena could reduce the life expectancy of cervical cancer patients. Resistance mechanisms are complex and often involve multiple cellular pathways in which microRNAs (miRNAs) play a fundamental role. miRNAs are a class of endogenous non-coding small RNAs responsible for post-transcriptional gene regulation. Convincing evidence demonstrates that several deregulated miRNAs are important regulators in the onset of drug and radioresistance in cervical cancer, thus underlying their potential applications in a clinical setting. In this review, we summarized the mechanisms by which miRNAs affect both cisplatin and radioresistance in cervical cancer. We also described the regulatory loops between miRNAs and lncRNAs promoting drug resistance. Besides, we reported evidence for the role of miRNAs in sensitizing cancer cells to cisplatin-based chemotherapy, and provided some suggestions for the development of new combined therapies for cervical cancer.

Entities:  

Keywords:  cervical cancer; cisplatin; cisplatin resistance; drug resistance; microRNA; radiotherapy

Year:  2021        PMID: 33803151      PMCID: PMC7963155          DOI: 10.3390/cancers13051168

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  98 in total

Review 1.  Natural history of cervical intraepithelial neoplasia: a critical review.

Authors:  A G Ostör
Journal:  Int J Gynecol Pathol       Date:  1993-04       Impact factor: 2.762

2.  MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase.

Authors:  Hui Yang; Xiao-Li Wu; Kai-Hua Wu; Rong Zhang; Li-Li Ju; Ying Ji; Yan-Wei Zhang; Song-Lin Xue; Ye-Xin Zhang; Yong-Feng Yang; Min-Min Yu
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

3.  Oncogenicity of LHX2 in pancreatic ductal adenocarcinoma.

Authors:  Feng Zhou; Shanmiao Gou; Jiongxin Xiong; Heshui Wu; Chunyou Wang; Tao Liu
Journal:  Mol Biol Rep       Date:  2014-10-17       Impact factor: 2.316

4.  Osteopontin expression correlates with invasiveness in cervical cancer.

Authors:  Jae Yun Song; Jae Kwan Lee; Nak Woo Lee; Bom Woo Yeom; Sun Haeng Kim; Kyu Wan Lee
Journal:  Aust N Z J Obstet Gynaecol       Date:  2009-08       Impact factor: 2.100

Review 5.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

6.  Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.

Authors:  David H Moore; Chunqiao Tian; Bradley J Monk; Harry J Long; George A Omura; Jeffrey D Bloss
Journal:  Gynecol Oncol       Date:  2009-10-22       Impact factor: 5.482

7.  Nuclear factor-κB-dependent microRNA-130a upregulation promotes cervical cancer cell growth by targeting phosphatase and tensin homolog.

Authors:  Yeqian Feng; Shenghua Zhou; Guiyuan Li; Chunhong Hu; Wen Zou; Haixia Zhang; Lili Sun
Journal:  Arch Biochem Biophys       Date:  2016-04-01       Impact factor: 4.013

Review 8.  Molecular mechanisms of cisplatin resistance in cervical cancer.

Authors:  Haiyan Zhu; Hui Luo; Wenwen Zhang; Zhaojun Shen; Xiaoli Hu; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2016-06-07       Impact factor: 4.162

9.  MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression.

Authors:  Z Fan; H Cui; H Yu; Q Ji; L Kang; B Han; J Wang; Q Dong; Y Li; Z Yan; X Yan; X Zhang; Z Lin; Y Hu; S Jiao
Journal:  Oncogenesis       Date:  2016-02-15       Impact factor: 7.485

10.  MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes.

Authors:  Fengxia Yang; Li Guo; Yujing Cao; Shizhen Li; Jianhua Li; Min Liu
Journal:  Med Sci Monit       Date:  2018-09-16
View more
  5 in total

1.  FOXA1 Leads to Aberrant Expression of SIX4 Affecting Cervical Cancer Cell Growth and Chemoresistance.

Authors:  Zhuo Wang; Bao-Sheng Sun; Zhi-Shen Chen; Kang-Kang Zhao; Yun-Long Wang; Fan-Xu Meng; Yang Zhang
Journal:  Anal Cell Pathol (Amst)       Date:  2022-04-20       Impact factor: 4.133

Review 2.  Role of NRF2 in Ovarian Cancer.

Authors:  Giovanni Tossetta; Sonia Fantone; Eva Montanari; Daniela Marzioni; Gaia Goteri
Journal:  Antioxidants (Basel)       Date:  2022-03-30

3.  linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer.

Authors:  Jing Tian; Lei Cheng; Enqi Kong; Wenjin Gu; Yuanyuan Jiang; Quan Hao; Beihua Kong; Li Sun
Journal:  Reprod Biol Endocrinol       Date:  2022-09-02       Impact factor: 4.982

Review 4.  Cisplatin for cancer therapy and overcoming chemoresistance.

Authors:  Ranmali Ranasinghe; Michael L Mathai; Anthony Zulli
Journal:  Heliyon       Date:  2022-09-14

5.  ADGRG1 Is a Predictor of Chemoresistance and Poor Survival in Cervical Squamous Carcinoma.

Authors:  Shuo Zhang; Kui Guo; Ying Liang; Kun Wang; Shuyan Liu; Xingsheng Yang
Journal:  Front Oncol       Date:  2021-07-22       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.